Drug-induced liver injury (DILI) is a leading cause of drug attrition during drug development and a common reason for drug withdrawal from the market. The poor predictability of conventional animal-based approaches necessitates the development of alternative testing approaches. A body of evidence associates DILI with the induction of stress-response genes in liver cells. Here, we set out to identify signal transduction pathways predominantly involved in the regulation of gene transcription by DILI drugs. To this end, we employed ATTAGENE's cell-based multiplexed reporter assay, the FACTORIAL transcription factor (TF), that enables quantitative assessment of the activity of multiple stress-responsive TFs in a single well of cells. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. Nat. Methods 5,[253][254][255][256][257][258][259][260]. Using this assay, we assessed TF responses of the human hepatoma cell line HepG2 to a panel of 64 drug candidates, including 23 preclinical DILI and 11 clinical DILI compounds and 30 nonhepatotoxic compounds from a diverse physicochemical property space. We have identified 16 TF families that specifically responded to DILI drugs, including nuclear factor (erythroid-derived 2)-like 2 antioxidant response element, octamer, hypoxia inducible factor 1 alpha, farnesoid-X receptor, TCF/beta-catenin, aryl hydrocarbon receptor, activator protein-1, E2F, early growth response-1, metal-response transcription factor 1, sterol regulatory element-binding protein, paired box protein, peroxisome proliferator-activated receptor, liver X receptor, interferone regulating factor, and P53, and 2 promoters that responded to multiple TFs (cytomegalovirus and direct repeat 3/vitamin D receptor). Some of TFs identified here also have previously defined role in pathogenesis of liver diseases. These data demonstrate the utility of cost-effective, animal-free, TF profiling assay for detecting DILI potential of drug candidates at early stages of drug development.
approaches to reliably predict the hepatotoxic potential of compounds, earlier in the drug development process.
A central challenge to the early detection of hepatotoxic drugs is the multifactorial nature of DILI. As a result, a variety of in vitro assays have been included into early drug screening (Shah et al., 2015) that evaluate an impairment of mitochondrial function (Porceddu et al., 2012) , inhibition of the bile salt export pump (BSEP) and other transporters involved in bile salt clearance from hepatocytes (Morgan et al., 2013) , reactive metabolite formation (Nakayama et al., 2009) , measurement of cellular health in the presence and absence of cytochrome P450 enzymes (Greer et al., 2009 ) and modulation of immune and inflammatory biomarkers (Oda et al., 2016) .
There is a body of evidence that DILI is associated with the activation of numerous stress and toxicity pathways that produce changes in gene expression (Yuan and Kaplowitz 2013) . At the apexes of signal transduction pathways that orchestrate gene transcription lie transcription factors (TFs), a class of regulatory proteins that bind specific sequences in target genes, thereby modulating transcription (Phillips and Hoopes, 2008) . There are numerous reports that exposure of liver cells to exogenous chemicals, including drugs, can affect the activity of multiple TFs, e.g., pregnane X receptor (PXR) and aryl hydrocarbon receptor (AhR) that mediate transcriptional responses to xenobiotics (Kliewer et al., 2002) , nuclear factor (erythroid-derived 2)-like 2 antioxidant response element (NRF2/ARE) (responsive to oxidative stress) (Ma, 2013) , p53 (responsive to DNA damage) (Meek, 2004) , hypoxia inducible factor 1 alpha (HIF-1a) (responsive to hypoxia) (Ziello et al., 2007) , and X-box binding protein 1 (XBP1) (responses to endoplasmic reticulum stress) (Calfon et al., 2002) . However, a systematic survey of DILI-specific TF responses has not been performed.
In this work, we set out to identify the TFs (and thus the corresponding upstream signal transduction pathways) specifically involved in cell responses to DILI drugs. To do that, we employed ATTAGENE FACTORIAL TF multiplexed reporter assay that enables quantitative assessment of the activity of multiple stress-and toxicity-relevant TFs in a single well of assay cells (Romanov et al., 2008) . Previously, ATTAGENE evaluated TF responses of human hepatocyte cells (HepG2) to over 1800 compounds, including environmental pollutants and failed drugs (Martin et al., 2010; . The analysis of these data revealed that several TFs (NRF2/ARE, peroxisome proliferator-activated receptor [PPAR] , and AhR) were modulated by hepatotoxic drugs. Here, we used the FACTORIAL TF assay to identify TF responses that were specifically associated with DILI drugs. To this end, we evaluated a panel of 64 drug candidates with or without evidence of liver injury and have identified a set of TFs that showed statistically significant correlation with hepatotoxic outcome.
MATERIALS AND METHODS
Tools used. Pipeline Pilot v9.0 custom scripting was used for data manipulation and analysis. The results were visualized using Spotfire DXP 6.5.3 and R version 3.2.2.
Chemical dataset, in vivo findings, and toxicity annotation. A total of 64 compounds were selected for these studies, 62 of which were available in the Pfizer chemical repository. and compound-23 (ADX-10059) were acquired from Sigma Aldrich, St. Louis, MO 63146. The exploratory in vivo safety studies for these compounds typically involved dose escalation studies over 3 or more dose levels for a duration of 14 days or longer in both rodents (rat, mouse) or nonrodents (dog, monkey). Eleven of 64 compounds, including cmpd-30 and cmpd-23, were evaluated in phases I-III clinical trials.
The compounds were classified as hepatotoxic in animal studies if severe liver findings were observed at a maximum total plasma exposure (Plasma C max, total ) of <10 mM. The signs of in vivo hepatotoxicity included an elevation of serum enzymes including alanine transaminases (ALT), alkaline phosphatase (ALP), and aspartate transaminase (AST), an increase in serum bile acids or serum bilirubin, and histology data, including liver hypertrophy, multifocal hepatocellular necrosis, cholestasis, inflammation or degeneration of hepatocytes. A total of 23 of 64 compounds meeting these criteria were classified as preclinical hepatotoxicants. The liver toxicity of these intrinsic hepatotoxicants was revealed by preclinical studies. The other set include hepatotoxicants, terminated due to elevation of liver transaminases in phases I-III clinical trials exceeding by more than 3 folds the upper limit of normal (ULN), will be referred to as "Clinical DILI". A total of 11 clinical DILI compounds were included in this set. Of interest, 9 of 11 Pfizer clinical DILI compounds did not show hepatotoxicity in in vivo animal studies or had a sufficient margin to in vivo effects in preclinical studies to enable their progression in clinical studies. The third set referred here as "nonhepatotoxicants" comprised 30 Pfizer compounds that had no evidence of liver toxicity up to C max, total of 10 mM. Most of these compounds were terminated in our preclinical studies due to toxicity to organs/tissues other than the liver. The 30 negative preclinical hepatotoxicants were never evaluated in clinical studies as many of them were discontinued due to other organ toxicity in preclinical studies or were deprioritized due to strategic reasons. This is an acknowledged limitation of our dataset. In summary, the evaluated compounds comprised 34 hepatotoxicants (n ¼ 23 preclinical hepatotoxicants and n ¼ 11 clinical DILI) and 30 nonhepatotoxic compounds. Table 1 provides an excerpt of in vivo findings for select compounds. The full list of in vivo data on these compounds and their plasma concentrations are shown by Supplementary Table 1. These compounds were from diverse therapeutic areas, gene families, and physicochemical property space. A distribution of physicochemical properties such as calculated lipophilicity (cLogP), calculated distribution coefficient (cPFLogD, as described in Aleo et al. [2017] ), molecular weight (MW), and polar surface area (PSA) of these compounds with respect to their hepatotoxicity potential is presented in Figure 1 .
The FACTORIAL TF assay. The ATTAGENE FACTORIAL TF assay comprises a set of 46 reporter constructs called reporter transcription units (RTUs). An RTU resembles a conventional reporter gene construct in that it has a TF-specific promoter that controls expression of a downstream reporter sequence. Being cotransfected into assay cells, the RTUs produce reporter RNAs proportionate to the activity of corresponding TFs. By detecting the profile of reporter transcripts, we assess the profile of the activity of the multiple TFs. The list of 46 TF endpoints of the FACTORIAL assay is shown in Table 2 .
Cells. The assay cells were a HG19 subclone of HepG2 (human liver hepatoma cell line, ATCC no. HB-8065) that was selected for an elevated metabolic activity due to a high-level expression of PXR and CYP450 enzymes. The FACTORIAL assay was reproduced as described previously (Romanov et al., 2008) . In brief, assay cells were transiently transfected with the plasmid RTU library. Twenty-four hours after transfection, cells were washed and incubated for 24 or 48 h in a low serum (1% Fetal Bovine Noncytotoxic compounds were evaluated by the FACTORIAL TF assay at the concentration of 10 mM. The TF profiling of compounds that were cytotoxic at 10 mM was done at a noncytotoxic concentration of 3 mM. The XTT cytotoxicity assay data at 10 mM for all compounds are listed in Supplementary Table 2 .
Data analysis. The endpoints of TF signatures are fold-induction values in drug-treated versus vehicle-treated cells. We calculated Mean 6 2SD of each TF modulated by nonhepatotoxicants at 24-h time point to select activity threshold for these TFs. Mean 6 2SD fold change values for a majority of TFs for nonhepatotoxic compounds were close to 1.5 6 0.75 as shown in Supplementary Figure 2 . In practice, it may be ideal to set a threshold for each TF based on the profile of nonhepatotoxicants. Since majority of nonhepatotoxicants used here also showed other organ toxicities in our preclinical studies (see Supplementary Table 1) , use of an explicit threshold for each TF using the activity profiles of nonhepatotoxicants from this study may not be recommended where our goal is to identify the TFs predictive of hepatotoxicity. Therefore, the same threshold was set for all 46 TF where a fold change of 1.5 or greater was used for the induction of TF whereas 0.75 and below was used for the suppression of TF activity to identify the TFs predictive of hepatotoxicity. We also examined reproducibility of these data by measuring similarity between 2 replicates at 24 and 48 h. For replicate analysis, a log 2 FC value was used to calculate Pearson correlation similarity using both up and down regulation of TFs between replicates. 
RESULTS
The complete dataset of 64 compounds, toxicity annotation and average (of 2 replicates) TF signatures at 24 and 48 h time points can be found in Supplementary Table 2 .
Cytotoxicity Analysis
The cytotoxicity assessment of all compounds was performed prior to running the TF Factorial profiling to establish a noncytotoxic concentration and eliminate nonspecific responses due to cytotoxicity. The results of XTT cell viability at 10 mM and 24 and 48 h time points are available in Supplementary Table 2 . At 24 h incubation at 10 mM, all compounds had >50% cell viability. At 48 h, Cmpd-7 significantly reduced cell viability (12%). Hence cmpd-7 was run at 3 mM at 48 h. After 48 h incubation, 2 other compounds (cmpd-30 and cmpd-19) also reduced cell viability (approximately 35%) at 48 h. As TF detection is based on PCR amplification, and the assay sensitivity does not suffer significantly at lower cell counts or partial RNA degradation, these 2 compounds were run at 10 mM concentrations at both time points. This is further confirmed by the overlay of TF profile of cmpd-19 and cmpd-30 at 24 and 48 h as shown in Supplementary Figure 3 .
Reproducibility of TF Signatures
To investigate the reproducibility of TF signatures, pairwise correlation analysis of replicates of was performed for all 64 compounds (Supplementary Figure 4) . In total 83% and 77% of replicates at 24 and 48 h had r ! 0.8, indicating strong concordance of duplicates at both time points. The average of 2 replicates was used in subsequent analysis.
Compound-Bioactivity Summary
Having identified the noncytotoxic concentration of these compounds and with confidence in data reproducibility, we analyzed TF responses at both time points. Figure 2A -2C show the unsupervised hierarchal clustering of TF profile of 64 compounds at 24 h, 48 h, as well as at both time points together. The hepatotoxic and nonhepatotoxic compounds formed isolated clusters as shown in Figure 2 as a result of unsupervised clustering. As shown in Figure 2C , profile of an individual compound at 24 and 48 h were clustered together for majority of compounds, further reassuring the reproducibility of data. The frequency of individual TF responses to hepatotoxicants was much higher than that to nonhepatotoxicants as shown in heat map at either time point. One exception was PXR that was nonspecifically activated by hepatotoxic and nonhepatotoxic compounds. A subset of TFs including FoXA2, GATA, GLI, HNF6, Myb, STAT3, NRF1 elicited either weak or no responses at both time points. Figure 3 shows the total number of affected TFs at 24 and 48 h by compounds. The changes of TF activity at 48 h were more pronounced as compared with 24 h. The hepatotoxic compounds affected a median of 4.0 and 6.5 TFs at 24 and 48 h, respectively. In contrast, nonhepatotoxicants affected a median of 1.5 and 2 TFs at 24 and 48 h, respectively. Most hepatotoxic compounds (47% at 24 h and 68% at 48 h) affected !5 TFs as compared with <10% of nonhepatotoxicants. Only 24% hepatotoxicants affected <2 TF at 24 and 48 h as compared with 63% and 76% of nonhepatotoxicants at similar time points. Hepatotoxicants with preclinical toxicity elicited more frequent TF responses as compared with clinical hepatotoxicants: 78% (18 of 23) of compounds with preclinical hepatotoxicity affected >4 TFs at 24 h as compared with 45% (5 of 11) of clinical hepatotoxicants. Accordingly, the numbers of clinical and preclinical hepatotoxicant that affected <2 TFs were 45% and 13%, respectively. A similar trend of TF responses was observed at 48 h. In summary, clinical hepatotoxicants showed modest TF response compared with preclinical hepatotoxicants from the present study.
Univariate Analysis of Individual TF Responses
Excluding PXR responses, up-regulation of at least 1 TF (!1.5fold) was seen in 68% of total compounds at 24 and 48 h whereas 48% and 42% of compounds from this dataset caused down-regulation of at least 1 TF (<0.75-fold induction) at 24 and 48 h, respectively. Using a univariate analysis, we correlated in vivo hepatotoxicity data with up-or downregulation of individual TFs.
We identified 18 RTUs that were significantly (p < .05) up-or downregulated by hepatotoxic compounds. At both 24 and 48 h time points, hepatotoxicants induced significant up regulation of NRF2/ARE, Octamer (Oct), HIF-1a, and direct repeat 3 (DR3)/vitamin D receptor (VDR) and downregulation of Farnesoid-X receptor (FXR) and TCF/beta-catenin RTUs. The associations that were significant at only 1 time point included upregulation of AhR, activator protein-1 (AP-1), cytomegalovirus (CMV) promoter, E2F, Early growth response protein (EGR), metal response element (MRE), sterol regulatory element-binding protein (SREBP), paired box protein (Pax6), and peroxisome proliferator-activated receptor (PPAR) (at 48 h) and downregulation of liver X receptor (LXR), IFN-stimulatory element (ISRE) and P53 RTUs (at 24 h). The most frequently responsive was the PXR RTU that was activated by approximately 68% of hepatotoxicants and 57% of nonhepatotoxicants (SE ! 68%, SP 47%) at 24 and 48 h. Figure 4 presents the sensitivity and specificity of all the TFs (a ROC curve). We also examined the correlation among 18 TF identified here at both time points (Supplementary Figure 5) . A high correlation (pearson correlation coefficient > 0.85) was observed for Pax6, EGR, HIF1a, and metal-response transcription factor 1 (MTF-1) at 24 and 48 h. Additionally, VDRE and Oct showed high correlation at 48 h. Some of these TF correlations can be attributed to their overlap in functions as shown in Table 3 .
Differential Modulation of Select TFs at 24 and 48 h by Hepatotoxic Compounds
We further investigated if differences in TF responses exist for hepatotoxicants at 24 versus 48 h time points using continuous values for each TFs and the Wilcoxon Sum Rank Test. The purpose here is to understand if select TFs are modulated by hepatotoxicants at 1 time point over the other in the same or opposite directions (induction vs suppression). We identified 3 TFs, namely AP-1, HNF6, and HIF-1a as differentially modulated for hepatotoxicants with a p value of < .05 at 24 versus 48 h. Supplementary Figure 6 shows all TF responses to hepatotoxicants at 24 and 48 h stimulation. Figure 5 show selected examples of these modulated TFs. For instance, at 24 h for a majority of hepatotoxicants the AP-1 response was below 1.2-fold, whereas >1.5-fold changes were noted at only 48 h time point. On the contrary for HIF-1a, an opposite response pattern was noted at 24 versus 48 h where majority of hepatotoxicants showed an increase in induction at 24 h compared to 48 h. For a subset of TFs like NRF2 and PPRE, a persistent increase in TF activity was noted up to 48 h in the same direction although the change was not significant according to applied Wilcoxon test (see Figure 5 ).
DISCUSSION
Cells respond to xenobiotics and stress by modulating expression of proteins that counteract the effects of dangerous stimuli. At the transcriptional level, cell response is coordinated by TFs that relay the signals from the upstream signal transduction pathways to the target genes thereby altering their transcription. It has been shown that hepatotoxic drugs can modulate the transcriptional activity of some TFs, but the systematic survey of DILI drug-responsive TFs has not been evaluated.
In this article, we assessed hepatotoxicant-induced changes of the activity of multiple TFs. To this end, we used a multiplexed reporter assay, the FACTORIAL TF that enables quantitative evaluation of the activity of multiple TFs in a single well of cells. A remarkable accuracy and reproducibility of the assay afforded statistically significant assessments of even weak (1.5-fold induction and 0.75 inhibition) TF responses. The FACTORIAL assay produces a multi-endpoint TF signature that characterizes a drug's impact on the activity of 46 TF families that mediate transcriptional responses to a variety of stress stimuli and xenobiotics. The assay was performed in a specially selected subclone of human hepatocyte cell line HepG2 that reproduces many features of response of normal hepatocytes to drugs and has elevated metabolic activity. In our study, we evaluated 64 structurally and therapeutically diverse compounds, including those that manifested hepatotoxicity in preclinical and clinical studies, using for comparison nonhepatotoxic compounds with other liabilities that prevented their further development.
A univariate analysis of 46 endpoints resulted in the identification of 18 RTUs that were predominantly affected by hepatotoxic drugs. Most of the corresponding TFs have established roles in the regulation of stress responses (NRF2, AP-1, HIF-1a), bile acid homeostasis (FXR and LXR), xenobiotic metabolism (AHR), cell cycle (p53 and E2F), and steatosis (SREBP and PPAR). Other specific TF responses to hepatotoxicants, including Oct, TCF/beta-catenin, ISRE, and Pax6, have not been previously associated with liver injury to the best of our knowledge. The responsiveness of the CMV RTU can be plausibly explained by the point that its promoter (the CMV immediate early enhancer) has binding sites for multiple stress-responsive TFs. Table 3 discusses the relevance of key TF identified in the present study to liver injury.
For some TFs that we identified as preferentially activated by hepatotoxic compounds, relatively straightforward links to in vivo hepatotoxicity can be established. For example, activation of FXR modulates transcription of multiple hepatobillary transporters. FXR up-regulation increases the expression of BSEP, multidrug resistance-associated protein 2 (MRP2), organic solute transporter expression and downregulates Na(þ)/taurocholate co-transporting polypeptide (NTCP) and organic anion transporting peptide (OATP) in hepatocytes (Rodrigues et al., 2014) . Thus FXR activation can increase the efflux of bile acids, exhibiting a protective response to the toxic effects of bile acids. Persistent downregulation of FXR by a drug can disrupt the adaptive ability of the liver and can exacerbate toxic effects of bile acids. In our analysis, persistent suppression of the transcriptional activity FXR by compounds with preclinical hepatotoxicity (cmpd-12, cmpd-24, cmpd-25, cmpd-28) and with clinical DILI (cmpd-30) correlated with inhibited BSEP function as determined by our internal BSEP vesicle assay (Shah et al., 2015) . Consistent with that, downregulation of FXR by Cmpd-30 (TAK-875) correlated with inhibited function of multiple hepatobillary transporters, including multidrug Mrp2, Ntcp, and OATP transporters, OATP1B1 and OATP1B3, and BSEP (Li et al., 2015; Shah et al., 2015) . Therefore, our TF data can be used in concert with established functional assays such as BSEP and other transporters for prediction of DILI potential. Nonhepatotoxic compounds from the current set did not modulate FXR suggesting low sensitivity but high specificity of FXR in DILI prediction.
Cell stimulation with hepatotoxicants produced consistent increase in TF activity at least at the 48 h time point for majority of TFs ( Figure 5 and Suppplementary Figure 6 ) that were significant in univariate analysis. Persistent activation of these TFs can exhaust the cells ability to produce the adaptive response and can lead to cell death via apoptosis and/or necrosis (Martin et al., 2010) . Only exception to this was HIF-1a where we saw opposite and adaptive response at 48 h by hepatotoxicants Figure 5 . Consideration of additional time points can further highlight the adaptive behavior of some of these TFs and may further assist in distinguishing hepatotoxicants from nonhepatotoxicants.
In the past few years, there have been multiple efforts across the industry to utilize basic drug design principles in terms of physicochemical properties or early higher throughput in vitro assays such as cytotoxicity or mitochondrial toxicity to prioritize compounds with high probability of success in in vivo studies (Shah et al., 2015; Thompson et al., 2012) . These approaches collectively have proven to be predictive of adverse safety outcome; however, often they fail to provide mechanistic understanding of a toxicity outcome (Greene and Song, 2011) . The TF panel presented here provides a mechanistic underpinning of in vivo toxicity. To further understand the advantage of TF profiling over physicochemical and cytotoxicity based approaches, TFs Involved in Stress Response NRF2/ARE Activation of NRF2/ARE is indicative of an adaptive response to cellular oxidative stress caused by oxidants and/or electrophiles. Oxidative stress is the result of an imbalance between oxidant and antioxidant agents, and is one of the causative factors for acute liver injury and chronic liver diseases. Recent studies showed that NRF2 mediates a protective response by induction of antioxidant genes, reduces the expression of genes linked to inflammation, and attenuates oxidative stress in response to hepatotoxicants that are known to produce reactive metabolite mediated stress or to elicit direct oxidative stress.
Ma (2013) HIF-1a activation has been implicated in several types of liver toxicity, including liver fibrosis, alcoholic liver disease, and hepatocellular carcinoma in both human and murine disease models. Both NRF2/ARE and HIFa have been shown to be upregulated by reactive oxygen species (ROS) from ethanol toxicity to provide protection to hepatocytes. Gunther et al. (2012) and Gunes et al. (1998) TFs Involved in the Regulation of Bile Acid Homeostasis FXR FXR is the key regulator of bile acid homeostasis in the liver. FXR increases expression of efflux transporters such as BSEP in response to increased bile salts in hepatocytes and triggers their efflux out of the hepatocytes. Thus, inhibition of FXR may play an important role in the development of liver cholestasis. FXR knockout mice displayed an elevated hepatic bile acid level which has been shown to promote inflammation, compensatory proliferation and hepatomegaly, and development of liver tumors. Rodrigues et al. (2014) , Kim et al. (2007) , and Manley et al. (2014) LXR LXR often acts as a liver protecting factor. Activation of LXR increases acetaminophen clearance and prevents its toxicity in mice. LXR activation also prevents bile acid toxicity in a liver induced by lithocholic acid. LXR inhibition by a drug may lead to bile acid accumulation leading to hepatotoxicity phenotypes. Saini et al. (2011) and Uppal et al. (2007) TFs Involved in Steatosis SREBP SREBP have been implicated in the development of fatty liver in alcoholic and nonalcoholic steohepatitis. SREBP-1 is also activated in the livers of chronic ethanol abusers. Ansari et al. (2016) PPAR PPARa is involved in the pathogenesis of liver diseases. PPARc mediates transcriptional activation of numerous adipogenic and lipogenic genes and may lead to disruption of cholesterol metabolism. Finally, activation of PPARa has been linked to the ability of a compound to induce liver cancer. Martin et al. (2010) TFs Involved in Xenobiotic Metabolism AhR AhR is induced in response to many strong hepatotoxic agents including genotoxins and polycyclic aromatic hydrocarbons (PAHs). AhR activation as the result of dioxin exposure is reported to show an adaptive metabolic response as well as a toxic response that includes hepatocellular damage. The mechanisms of AhR-dependent toxicity include induction of Cyp1A1 that results in oxidative stress and wasting syndrome after dioxin exposure. Yoshioka et al. (2011) TFs Involved in Cell Cycle Regulation E2F E2F transcription factors are key regulators of the cell cycle, proliferation, apoptosis, and differentiation. E2F up-regulation is part of the checkpoint transcriptional response to DNA damage. As a consequence of genotoxic stress, E2F1 protein is stabilized resulting in stimulation of DNA repair. E2F1 also contributes to the development of liver pathology by regulating lipid synthesis and glycolysis during hepatic steatosis. Bertoli et al. (2013) , Biswas et al. (2014) , and Denechaud et al. (2016) Miscellaneous Functions DR3/VDR The promoter of VDR RTU has multiple copies of DR3 that are binding sites for VDR. However, the HepG2 assay cells do not express VDR and do not respond to stimulation with Vitamin D (data not shown). Thus, the upregulation of the DR3/VDR RTU was due to the binding of other TFs, such as PXR that binds the DR3 as a heterodimer with RXR. Analysis of the ATTAGENE database shows that induction or suppression of VDRE in HepG2 cells by various compounds moderately correlates with induction of PXRE (r ¼ 0.55 across 32, 673 response profiles). Thus, in some occasions, the binding of PXR to the promoter of VDR RTU may cause its activation. However, this fact alone does not account for the differential responsiveness of the VDR RTU to hepatotoxicants. Thus the identity of the TFs mediating the preferential induction of DR3/VDR RTU is yet to be revealed. Kliewer et al. (1998) we compared the number of TFs modulated by these compounds at the 24 h time point with cytotoxicity in THLE cell lines and lipophilicity. The results for correlation of cytotoxicity and lipophilicity for 64 compounds to the number of TFs modulated (<0.75x ¼ downregulation; >1.5x ¼ upregulation) are summarized in Figure 6 . All compounds were bucketed in higher (clogP > 3) versus lower (clogP < 3) lipophilicity or higher (<10 mM), middle (10-50 mM) and lower (>50 mM) cytotoxicity bins and by number of TF they modulate at the 24 h time point (<3; 3-5 and >5) this analysis. Although compounds with >5 TF activity had greater prevalence for higher lipophilicity, it did not seem to be the driving factor for TF activity. This is evident as 4 compounds with clogP <3 also showed modulation of >5 TFs. In addition, 14 of 33 compounds showed activity against <3 TF despite clogP of >3. We did not see a significant trend for higher TF modulation at 10 mM with lower cytotoxicity (THLE < 50 mM) as shown in Figure 6B . All compounds with THLE <10 mM and >5 TF modulation are kinase inhibitors and their low cytotoxicity may be a reflection of their antiproliferative activity by inhibition of phosphorylation of multiple TFs. In addition, 8 compounds with THLE > 50 mM also modulated >5 TFs. It is to be noted that some of the modulations of these signal transduction pathways are associated with apoptosis (e.g., decrease in p53) which may lead to cell death. Moreover, as shown in Figure 1 , physicochemical properties such as clogP, PFLogD, MW, and PSA of these 64 compounds alone are not predictive of hepatotoxicity. This does emphasize the multifactorial nature of predicting hepatotoxicity that cannot simply be explained by physicochemical properties. The analysis presented herein highlights the advantage of TF screening platform over a simple cytotoxicity or physicochemical properties based approach in prioritizing drug candidates. The routine use of in vitro off-target pharmacology panels is an important way to focus on drug safety much earlier in the drug discovery process, with a goal to reduce attrition due to safety in later stages. The multiplexed TF panel utilized here can be used early-on for hazard identification. Early profiling of compounds against these in vitro high throughput assays related to stress and toxicity can enable medicinal chemists to identify chemical series lacking this activity and helping them to prioritize compounds for in vivo rodent/nonrodent studies. For instance, compounds with no TF activity or relatively cleaner TF profile can be prioritized over those with multiple TF activities for preclinical animal studies. A typical cost-effective early screening strategy should be to spot check compound activity in this multiplexed TF panel using multiple replicates of 2-3 representatives from each chemical series at a single concentration with a goal to identify compound/series specific TFs activities. Compounds with multiple TF activities or strong modulation of a TF can then be followed up in a dose response manner to better understand the safety margin when anticipated efficacious exposure is available. Ultimately, one can also envision a mini panel with only those TFs with a higher correlation to hepatotoxicity to be a cost-effective screening approach to prioritize chemicals with less likelihoods of hepatotoxicity. In summary, we evaluated the correlation of select TFs with the hepatotoxic outcome from preclinical or clinical studies at toxicologically relevant concentrations of 10 mM. A majority of hepatotoxicants modulated a greater number and magnitude of TF responses than nonhepatotoxicants at 48 h, although the response for hepatotoxicants for the majority of TFs at both time points was in the same direction (induction vs suppression). Univariate analysis helped to identify 18 of 46 distinct stress/ toxicity related TFs at either time point as differentiating hepatotoxicants from nonhepatotoxicants. Some of these TFs play a critical role in the pathogenesis of liver diseases thus providing additional biological relevance to use these TFs in understanding the mechanisms of hepatotoxicity. Further understanding of collective TF response patterns to identify bioactivity signatures and their biological significance may shed light on common molecular initiating events leading to hepatotoxicity for these compounds and is currently underway. The in vitro TF profiling presented here provides a cost-effective approach for selection of drug candidates with less likelihood of DILI at the later stages of drug development.
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